Predicting Outcomes in Sarcoma Herpesvirus-Associated Castleman's Disease

Thomas Uldrick, MD, ‎Staff Clinician at the National Cancer Institute of the National Institutes of Health discusses what baseline measures will help predict outcomes in patients with sarcoma herpesvirus-associated Casteleman's disease.

Source
Uldrick A, Polizzotto MN, Goncalves P, et al. Outcomes in Kaposi sarcoma herpesvirus-­‐associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-­‐Dox). Hematol Oncol. 2015; 33(suppl):201. Presented at: 13th International Conference of Malignant Lymphoma; Lugano, Switzerland; June 17-20, 2015.